On Friday, a panel of experts selected by the Food and Drug Administration will convene to vote on whether aducanumab, an Alzheimer’s treatment developed by Biogen, deserves to win approval.

STAT Plus subscribers will have access to all-day coverage of the Friday meeting, with updates summarizing key presentations, interesting arguments, and eventually the outcome itself.

Stay tuned.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]